Olema Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Olema Pharmaceuticals es Sean Bohen , nombrado en Sep 2020, tiene una permanencia de 4.17 años. compensación anual total es $3.15M, compuesta por 20.5% salario y 79.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.25% de las acciones de la empresa, por valor de $1.47M. La antigüedad media del equipo directivo y de la junta directiva es de 3.5 años y 4.3 años, respectivamente.
Información clave
Sean Bohen
Chief Executive Officer (CEO)
US$3.2m
Compensación total
| Porcentaje del salario del CEO | 20.5% |
| Permanencia del CEO | 4.2yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 3.5yrs |
| Promedio de permanencia en la Junta Directiva | 4.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Aug 29
Olema Pharmaceuticals: Still Merits A Small Holding
Jun 17Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
May 11Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
Mar 28Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Mar 04Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
Nov 09We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Jun 11Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?
Mar 01Olema Oncology grants stock options for 58.3K shares
Oct 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 13Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18
Aug 09Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype
Jul 21We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth
May 29Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 08Our Take On Olema Pharmaceuticals
Jan 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 19We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth
Jun 04Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 19
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$123m |
| Jun 30 2024 | n/a | n/a | -US$110m |
| Mar 31 2024 | n/a | n/a | -US$99m |
| Dec 31 2023 | US$3m | US$647k | -US$97m |
| Sep 30 2023 | n/a | n/a | -US$96m |
| Jun 30 2023 | n/a | n/a | -US$97m |
| Mar 31 2023 | n/a | n/a | -US$110m |
| Dec 31 2022 | US$6m | US$616k | -US$105m |
| Sep 30 2022 | n/a | n/a | -US$100m |
| Jun 30 2022 | n/a | n/a | -US$95m |
| Mar 31 2022 | n/a | n/a | -US$79m |
| Dec 31 2021 | US$3m | US$595k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$60m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$11m | US$178k | -US$24m |
Compensación vs. Mercado: La compensación total de Sean($USD3.15M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.12M).
Compensación vs. Ingresos: La compensación de Sean ha sido consistente con los resultados de la empresa en el último año.
CEO
Sean Bohen (57 yo)
4.2yrs
Permanencia
US$3,152,370
Compensación
Dr. Sean P. Bohen, M.D., Ph.D. has been a Director at AltruBio, Inc. He is the Chief Executive Officer and Director of Olema Pharmaceuticals, Inc. since September 2020 and serves as its President. He serve...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.2yrs | US$3.15m | 0.25% $ 1.5m | |
| Chief Operating & Financial Officer | 4.4yrs | US$1.55m | 0.89% $ 5.2m | |
| Chief Medical Officer | 2.8yrs | US$1.30m | 0.16% $ 909.0k | |
| Vice President of Corporate Communications | less than a year | sin datos | sin datos | |
| Senior VP & Head of People | no data | sin datos | sin datos | |
| Chief Discovery & Non-Clinical Development Officer | 4.4yrs | US$200.00k | 1.3% $ 7.5m | |
| VP of Finance & Controller | 1.8yrs | sin datos | sin datos |
3.5yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de OLMA se considera experimentado (3.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.2yrs | US$3.15m | 0.25% $ 1.5m | |
| Independent Director | 11.8yrs | US$176.65k | 0.67% $ 3.9m | |
| Independent Director | 4.3yrs | US$180.15k | 0.15% $ 848.8k | |
| Independent Chairperson of the Board | 4.3yrs | US$198.65k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 3.6yrs | US$11.81k | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4yrs | US$158.15k | 0% $ 0 | |
| Independent Director | 1.1yrs | US$280.21k | 0% $ 0 | |
| Independent Director | 4.7yrs | US$171.15k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$163.15k | 0% $ 0 | |
| Independent Director | 6.3yrs | US$165.15k | 0% $ 0 | |
| Director | 18.3yrs | US$1.33m | 1.53% $ 8.8m |
4.3yrs
Permanencia media
60yo
Promedio de edad
Junta con experiencia: La junta directiva de OLMA se considera experimentada (4.3 años de antigüedad promedio).